Market Overview

From Earlier: Illumina Launches Infinium HumanCore Arrays for Economical Large-Scale Genetic Studies

Share:
Related ILMN
Illumina Reported Its Fastest Top-line Growth Since 2015
Benzinga's Top Upgrades, Downgrades For October 25, 2017
Your Daily Pharma Scoop: Celgene Upside, Erytech Tumbles, Novartis Neulasta Biosimilar (Seeking Alpha)

Illumina, Inc. (NASDAQ: ILMN) today launched the Infinium HumanCore BeadChip family of products. With content developed in collaboration with several leading research institutions, the customizable Infinium HumanCore and Infinium HumanCoreExome BeadChips support cost-effective, large-scale genotyping and screening studies such as those performed by biobanks, genome centers, and core labs. Based on Illumina's proven Infinium assay, the BeadChips enable genotyping of markers found across diverse populations, making them ideal for researchers engaged in population genetics studies around the world.

Posted-In: News FDA

 

Related Articles (ILMN)

View Comments and Join the Discussion!

Partner Center